ALK2 and BMPR2 knockdown and endothelin-1 production by pulmonary microvascular endothelial cells

Microvascular Research

Volumn 85, Issue 1, 2013, Pages 46-53

  Star, Gregory P ^a   Giovinazzo, Michele ^a   Langleben, David ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN LIKE KINASE 1; ACTIVIN LIKE KINASE 2; ACTIVIN LIKE KINASE 5; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CELL ENZYME; ENDOTHELIN 1; ENDOTHELIN B RECEPTOR; INHIBITOR OF DIFFERENTIATION 1; PHOSPHOTRANSFERASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMAD1 PROTEIN; SMAD2 PROTEIN; SMAD5 PROTEIN; SMALL INTERFERING RNA; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ENDOTHELIUM; MICROVASCULAR ENDOTHELIAL CELL; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

ACTIVIN RECEPTORS, TYPE I; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIN-1; GENE EXPRESSION REGULATION; HUMANS; LUNG; MICROCIRCULATION; MODELS, BIOLOGICAL; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84871719403     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2012.10.012     Document Type: Article

References (44)

1. Albinana V., et al. Immunosuppressor FK506 increases endoglin and activin receptor-like kinase 1 expression and modulates transforming growth factor-beta1 signaling in endothelial cells. Mol. Pharmacol. 2011, 79:833-843.
2. Aoki H., et al. Synergistic effects of different bone morphogenetic protein type I receptors on alkaline phosphatase induction. J. Cell Sci. 2001, 114:1483-1489.
3. Benezra R., et al. The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 1990, 61:49-59.
4. Bocciardi R., et al. Mutational analysis of the ACVR1 gene in Italian patients affected with fibrodysplasia ossificans progressiva: confirmations and advancements. Eur. J. Hum. Genet. 2009, 17:311-318.
5. Castanares C., et al. Signaling by ALK5 mediates TGF-beta-induced ET-1 expression in endothelial cells: a role for migration and proliferation. J. Cell Sci. 2007, 120:1256-1266.
6. De Nucci G., et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:9797-9800.
7. Deng Z., et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenic protein receptor-II gene. Am. J. Hum. Genet. 2000, 67:737-744.
8. Dresdale D.T., et al. Primary pulmonary hypertension 1. Clinical and hemodynamic study. Am. J. Med. 1951, 11:686-705.
9. Dupuis J., Hoeper M.M. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur. Respir. J. 2008, 31:407-415.
10. B receptors. J. Appl. Physiol. 1996, 81:1510-1515.
11. Giaid A., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 1993, 328:1732-1739.
12. Goodall T., et al. FK506-induced endothelin release by cultured rat mesangial cells. J. Cardiovasc. Pharmacol. 1995, 26(Suppl. 3):S482-S485.
13. Herrera B., et al. Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian cancer cell proliferation. Cancer Res. 2009, 69:9254-9262.
14. Kugimiya F., et al. Mechanism of osteogenic induction by FK506 via BMP/Smad pathways. Biochem. Biophys. Res. Commun. 2005, 338:872-879.
15. Lane K.B., et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat. Genet. 2000, 26:81-84.
16. Macias-Silva M., et al. Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2. J. Biol. Chem. 1998, 273:25628-25636.
17. Marsen T.A., et al. Differential transcriptional regulation of endothelin-1 by immunosuppressants FK506 and cyclosporin A. Fundam. Clin. Pharmacol. 2000, 14:401-408.
18. McLaughlin V.V., et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J. Am. Coll. Cardiol. 2009, 53:1573-1619.
19. Michael J.R., Markewitz B.A. Endothelins and the lung. Am. Rev. Respir. Dis. 1996, 154:555-581.
20. Miyazono K., et al. Bone morphogenetic protein receptors and signal transduction. J. Biochem. 2010, 147:35-51.
21. Morrell N.W. Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling?. Proc. Am. Thorac. Soc. 2006, 3:680-686.
22. Morrell N.W. Role of bone morphogenetic protein receptors in the development of pulmonary arterial hypertension. Adv. Exp. Med. Biol. 2010, 661:251-264.
23. Morrell N.W., et al. Cellular and molecular basis of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2009, 54:S20-S31.
24. Newman J.H., et al. Narrative review: the enigma of pulmonary arterial hypertension: new insights from genetic studies. Ann. Intern. Med. 2008, 148:278-283.
25. Orlova V.V., et al. Controlling angiogenesis by two unique TGF-beta type I receptor signaling pathways. Histol. Histopathol. 2011, 26:1219-1230.
26. Park J.E., et al. BMP-9 induced endothelial cell tubule formation and inhibition of migration involves Smad1 driven endothelin-1 production. PLoS One 2012, 7:e30075.
27. Perez del Villar C., et al. Role of endothelin in the pathogenesis of hypertension. Mayo Clin. Proc. 2005, 80:84-96.
28. Ponticelli C. Present and future of immunosuppressive therapy in kidney transplantation. Transplant. Proc. 2011, 43:2439-2440.
29. Provencher S., et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur. Heart J. 2006, 27:589-595.
30. Rodriguez-Pascual F., et al. Functional cooperation between Smad proteins and activator protein-1 regulates transforming growth factor-beta-mediated induction of endothelin-1 expression. Circ. Res. 2003, 92:1288-1295.
31. Scharpfenecker M., et al. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J. Cell Sci. 2007, 120:964-972.
32. Slowinski T., et al. Interaction of the endothelin system and calcineurin inhibitors after kidney transplantation. Clin. Sci. (Lond.) 2002, 103(Suppl. 48):396S-398S.
33. Song G.A., et al. Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva. J. Biol. Chem. 2010, 285:22542-22553.
34. Star G.P., et al. Effects of bone morphogenic proteins and transforming growth factor-beta on in-vitro production of endothelin-1 by human pulmonary microvascular endothelial cells. Vasc. Pharmacol. 2009, 50:45-50.
35. Star G.P., et al. Bone morphogenic protein-9 stimulates endothelin-1 release from human pulmonary microvascular endothelial cells: a potential mechanism for elevated ET-1 levels in pulmonary arterial hypertension. Microvasc. Res. 2010, 80:349-354.
36. Star G.P., et al. Knockdown of bone morphogenic protein receptor-II by siRNA increases in vitro endothelin-1 synthesis by human pulmonary microvascular endothelial cells. Proc. Brit. Pharmacol. Soc. 2011, http://www.pA2online.org/abstracts/Vol9Issue1abst025P.pdf.
37. Stewart D.J., et al. Increased Plasma Endothelin-1 in Pulmonary Hypertension: Marker or Mediator of Disease?. Ann. Intern. Med. 1991, 114:464-469.
38. Talati M., et al. BMPR2 mutation alters the lung macrophage endothelin-1 cascade in a mouse model and patients with heritable pulmonary artery hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 2010, 299:L363-L373.
39. Textor S.C., et al. Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation. Kidney Int. 1995, 47:1426-1433.
40. Tuder R.M., et al. Development and pathology of pulmonary hypertension. J. Am. Coll. Cardiol. 2009, 54:S3-S9.
41. Upton P.D., Morrell N.W. TGF-beta and BMPR-II pharmacology-implications for pulmonary vascular diseases. Curr. Opin. Pharmacol. 2009, 9:274-280.
42. Valdimarsdottir G., et al. Stimulation of Id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells. Circulation 2002, 106:2263-2270.
43. Yang X., et al. Expression of mutant BMPR-II in pulmonary endothelial cells promotes apoptosis and a release of factors that stimulate proliferation of pulmonary arterial smooth muscle cells. Pulm. Circ. 2011, 1:103-110.
44. Yu P.B., et al. Bone morphogenetic protein (BMP) type II receptor deletion reveals BMP ligand-specific gain of signaling in pulmonary artery smooth muscle cells. J. Biol. Chem. 2005, 280:24443-24450.